In the 13 years Innovent Biologics has rapidly grown into a leading biopharmaceutical company in China. Under the
guidance of the “sustainable development and global innovation” strategy, we have continuously
achiev excellent results. At the beginning of the new buy bulk sms service year, the company has made important progress:
two lung cancer target drugs, Dabolu® and Aoyixin® , were approv in succession, and the number of
commercial products increas to 14; Similac® was includ in the mical insurance implementation,
becoming the first and only domestic PCSK9 inhibitor includ in the mical insurance; sign a US$1 billion
licensing cooperation with Roche to jointly promote the global development of ADC drugs; and further
expand strategic cooperation with Eli Lilly to commercialize the latest blood tumor variety Jepali® .
With concentrat efforts in R&D, IBI363 was grant the FDA fast track review and IBi343 was grant the
breakthrough development channel, which comprehensively accelerat the internationalization process.
Looking ahead
Innovent Biologics has a clear strategy and is being steadily implement. 2025 will be an important
year for entering a new era of dualwheel drive and global innovation and development.
The business will move forward and innovation understand the benefits of itil for cost reduction will strive for breakthroughs. The company is steadily
moving towards its vision of “becoming a worldclass biopharmaceutical company.”
Bipolar drive, the path to sustainable development becomes clearer
After years of hard work, Innovent Biologics has become a leading brand in China’s cancer treatment
field, and continues to promote the launch of new products and latestage clinical development.
At the same time, as the second growth
Pole of the company’s growth, the comprehensive product line will unlock more market space for
chronic diseases with the launch of a number trust review of blockbuster new drugs in 2025.
Innovent Biologics is increasingly confident in achieving its goal of RMB 20 billion in domestic product
revenue by 2027. While maintaining rapid growth in business scale, it will continue to improve its lean operations, be profitorient, and move toward a sustainable development operating model In the 13 years.